IBS Digital therapeutic Parallel™ developed by King’s researchers gets approval in UK and US
Parallel™ is the first prescription only digital therapeutic to provide cognitive behavioural therapy (CBT) to adults with irritable bowel syndrome (IBS) to receive the FDA Marketing Authorization in the US. ParallelTM has also obtained a CE mark and been recommended for Evaluation in Practice by the National Institute for Health and Care Excellence (NICE).
By NIHR Maudsley BRC at 1 Apr 2021